The COVID-19 pandemic has impacted the care of countless individuals, including pediatric oncology patients. The initial lack of knowledge about the disease course and implications of infection led to delays in treatment to minimize additional harm. In pediatric oncology, unnecessary delays in chemotherapy or hematopoietic stem cell transplantation may increase the risk of disease relapse. This case report describes one high-risk pediatric oncology patient’s clinical course through hematopoietic stem cell transplantation immediately following COVID-19 infection complicated by multisystem inflammatory syndrome in children. The disease course, monitoring, long-term outcome, and recommendations for future research are reviewed.
【저자키워드】 COVID-19, MIS-C, pediatrics, leukemia, Hematopoietic stem cell transplant, 【초록키워드】 Treatment, knowledge, pediatric, children, COVID-19 pandemic, Infection, risk, outcome, Case report, Chemotherapy, Clinical course, COVID-19 infection, oncology, Research, Patient, disease, Care, Inflammatory, Stem cell transplantation, disease course, syndrome, oncology patients, recommendation, implication, initial, Course, lack, the disease, individuals, impacted, 【제목키워드】 Transplant, hematopoietic, STEM,